White Paper: Building the Future of Food with Precision Fermentation's Proven Workhorse
The Power of Trichoderma reesei
Building the Future of Food with Precision Fermentation's Proven Workhorse
Author: Christopher P. Landowski, Ph.D.
Chief Technology Officer & Co-Founder, Onego Bio
December 2025
Executive Summary
Trichoderma reesei is one of the most validated industrial platforms for commodity-scale protein production. With documented secretion titers exceeding 110 grams per liter—far surpassing all other non-filamentous hosts—and a 50+ year safety track record, this filamentous fungus has quietly become the workhorse behind the world's largest enzyme manufacturers. Today, pioneering food technology companies are leveraging this proven industrial heritage to produce animal-free food proteins at scale.
This white paper examines why T. reesei has earned its position as the optimal chassis for precision fermentation, drawing on decades of scientific development and industrial validation. The convergence of exceptional protein secretion capacity, uncoupled growth and production phases, simple glucose-based media requirements, and established regulatory acceptance positions this organism uniquely among all available production platforms.
For companies seeking to scale commodity food ingredients through precision fermentation, T. reesei offers not merely a production platform but an entire ecosystem of validated technology, know-how and available infrastructure, regulatory precedent, and scientific expertise. The organism that once rotted military equipment in the Solomon Islands jungle now stands as the foundation for biotechnology's next frontier: animal-free food production at global scale.
Key Findings
• Protein secretion capacity exceeding 110 g/L—5x higher than yeast platforms
• Adopted by all major enzyme manufacturers: IFF, Novonesis, AB Enzymes, DSM-Firmenich
• FDA GRAS status since 1999; 25 GRAS notifications received “no questions” letters
• Industrial-scale fermentation proven at 150,000–350,000 liter volumes
• Simple defined glucose-based media; no inducers required with modern strains
Download a copy:
Please fill out the form below to download a copy of the white paper.
Contact:
Christopher P. Landowski, Ph.D.
Chief Technology Officer & Co-Founder, Onego Bio